Cellular Biomedicine Group Inc. (CBMG) Plunges 6.52% on March 15

Equities Staff  |

Cellular Biomedicine Group Inc. (CBMG) had a rough trading day for Friday March 15 as shares tumbled 6.52%, or a loss of $-1.12 per share, to close at $16.05. After opening the day at $17.18, shares of Cellular Biomedicine Group Inc. traded as high as $17.43 and as low as $15.90. Volume was 161,452 shares over 833 trades, against an average daily volume of n/a shares and a total float of 18.08 million.

As a result of the decline, Cellular Biomedicine Group Inc. now has a market cap of $290.21 million. In the last year, shares of Cellular Biomedicine Group Inc. have traded between a range of $25.00 and $12.04, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

For a complete fundamental analysis of Cellular Biomedicine Group Inc., check out Equities.com’s Stock Valuation Analysis report for CBMG.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.

Cellular Biomedicine Group Inc. is based out of New York, NY and has some 193 employees. Its CEO is Bizuo Liu.

Cellular Biomedicine Group Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Cellular Biomedicine Group Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: CBMG’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

World Economic Forum at Davos 2019 - Frank Ricotta CEO BurstIQ

Matt Bird sits down with Frank Ricotta, CEO BurstIQ, at the World Economic Forum at Davos 2019